DIH

Dihexa

Cognitive Preclinical (animal)

Synthetic peptide derived from angiotensin IV. A 2014 study of cultured hippocampal neurons and rodents, since retracted (2025), reported that dihexa promoted spinogenesis at picomolar concentrations. No human studies have been published.

Regulatory status (as of Sept 2026)

Not FDA-approved, no IND-stage human data published. Dihexa is slated for a PCAC review before the end of February 2027; PCAC output is advisory only and rulemaking would be required for any change.

See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote
Educational summary. Every effect described below is drawn from the cited published research and describes what was observed in research subjects — not a promise of results, a dose recommendation, or an endorsement for human use. Many peptides are not FDA-approved. Consult a licensed healthcare provider before making any health decision. Full disclaimer.

2 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content

TL;DR — Dihexa at a Glance

Dihexa is a compound studied only in animals and lab experiments so far. Synthetic peptide derived from angiotensin IV.

Half-lifeNot established in published research
How it's given in studiesOral or intraperitoneal (rodent studies only); no human administration published
Research stagePreclinical (animal)
Dosing
Published research: No published human dosing
detailsRodent and cell-culture work only: picomolar-to-nanomolar concentrations in hippocampal culture assays, and orally administered dihexa in rat models of cognitive impairment. No human dosing has been published.
Community-reportedCommunity-reported: 10–40 mg oral, oral or subcutaneous

Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.

Where each point comes from: Clinicalhuman trials and FDA labels   Lab / animalrodent, cell and ex vivo studies   Community-reporteduser experience and commonly used protocols, not from clinical studies

How It Works

In plain terms: It is thought to boost a growth-factor system that helps nerve cells form connections, but the main study behind this was retracted. Proposed mechanism: activation of the hepatocyte growth factor (HGF)/c-Met system, promoting synaptogenesis at picomolar concentrations in cultured neurons. The main study proposing this mechanism (Benoist 2014, cultured neurons and rodents) was retracted in 2025; the other cited source is a narrative review of angiotensin IV analogue development (Wright 2015). No human studies have been published.

Effects Reported in Research

How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.

  • Lab / animalImproved performance in rat models of cognitive impairment; no human studies
  • Lab / animalIn animal studies: neuroplasticity
  • Lab / animalSpinogenesis/synaptogenesis in cultured hippocampal neurons (in vitro), reported in a 2014 study that was retracted in 2025

What Users Report (Community, Not Clinical)

Commonly reported protocol

Community-reportedSome users report running Dihexa at 10–40 mg (oral or subcutaneous). This is not a recommendation.

Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.

Side Effects and Safety Notes

  • No human safety data have been published
  • Toxicology is uncharacterized; the proposed HGF/c-Met mechanism is a growth-factor pathway implicated in tumor biology, which is an unresolved theoretical concern
  • Lab / animalAll reported effects come from cell-culture and rodent studies

References

  1. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system
    Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM et al. The Journal of pharmacology and experimental therapeutics. 2014. PMID: 25187433.
    Study type: RETRACTED in 2025 (retraction notice PMID 40312093). In vitro neuronal culture plus rodent mechanistic study.
    DOI: 10.1124/jpet.114.218735 · PubMed
  2. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases
    Wright JW, Kawas LH, Harding JW. Progress in neurobiology. 2015. PMID: 25455861.
    Study type: Narrative review of preclinical angiotensin IV analog development.
    DOI: 10.1016/j.pneurobio.2014.11.004 · PubMed

Get the weekly Dispatch

New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.

How Dihexa Compares

PeptideHalf-LifeRouteResearch Status
DihexaUnknownOral or intraperitoneal (rodent studies only); no human administration publishedPreclinical (animal)
FGL (L)UnknownSubcutaneous injectionPreclinical (animal)
P21UnknownOral (mice)Preclinical (animal)
PE-22-28No published PK data foundSubcutaneous injection, IntranasalPreclinical (animal)
PinealonNo published PK data foundOral, SublingualPhase 1 / early human

Values reflect figures reported in published research. Compare any peptides side-by-side →

Frequently Asked Questions

What is Dihexa?
Synthetic peptide derived from angiotensin IV. A 2014 study of cultured hippocampal neurons and rodents, since retracted (2025), reported that dihexa promoted spinogenesis at picomolar concentrations. No human studies have been published.
How does Dihexa work?
In plain terms: It is thought to boost a growth-factor system that helps nerve cells form connections, but the main study behind this was retracted. Proposed mechanism: activation of the hepatocyte growth factor (HGF)/c-Met system, promoting synaptogenesis at picomolar concentrations in cultured neurons. The main study proposing this mechanism (Benoist 2014, cultured neurons and rodents) was retracted in 2025; the other cited source is a narrative review of angiotensin IV analogue development (Wright 2015). No human studies have been published.
What is the research status of Dihexa?
Dihexa is at the following stage in the published literature: Preclinical (animal). All information is for research and educational purposes only.
What is the half-life of Dihexa?
Reported half-life: Unknown.
How is Dihexa administered in research?
Reported administration route in the literature: Oral or intraperitoneal (rodent studies only); no human administration published. This is not a recommendation for human use.

Quick Actions

Category

This peptide belongs to the Cognitive category. View All Cognitive Peptides

Related Peptides

  • FGL (L) (FGL, Cognitive) — View Profile
  • P21 (P21, Cognitive) — View Profile
  • PE-22-28 (PE22, Cognitive) — View Profile
  • Pinealon (PIN, Cognitive) — View Profile

From Our Affiliated Clinic

Prefer physician oversight? See how 1836 Wellness works.

1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.

See how it works →

Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.

Sources & Methodology

Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.

← Back to Peptide Library Dosing Calculator The Dispatch Home